rosuvastatin / Generic mfg. - LARVOL DELTA

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia. (clinicaltrials.gov) - P3 | N=228 | Recruiting | Sponsor: EMS | Trial completion date: Aug 2025 ➔ Sep 2027 | Trial primary completion date: Apr 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment (clinicaltrials.gov) - P3 | N=146 | Completed | Sponsor: EMS | N=298 ➔ 146 | Trial completion date: Feb 2025 ➔ Jul 2025 | Recruiting ➔ Completed

Enrollment change • Trial completion • Trial completion date • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Genetic Disorders • Obesity

Renal Toxicity of Rosuvastatin: A Case Report. (PubMed, Cureus) - "He had initially been treated with simvastatin, though it was changed to rosuvastatin for stronger effects on cholesterol and cardiovascular risk reduction. He had severe esophageal disease, which was at risk of a flare with coming off the pantoprazole, so we elected to stop rosuvastatin first. After stopping rosuvastatin, the kidney function returned to baseline, and the abnormal urine testing resolved."

Journal • Acute Kidney Injury • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Gastrointestinal Disorder • Hypertension • Nephrology • Renal Disease

Statin-Induced Decade-Long Stabilization of Noncalcified Coronary Plaque Despite a Zero Calcium Score. (PubMed, JACC Case Rep) - "AI-quantified CCTA reveals subclinical atherosclerosis invisible to CAC 0 scoring and enables plaque-directed therapy monitoring in individual patients."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

EURO-CBI: A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (clinicaltrials.gov) - P3 | N=1652 | Recruiting | Sponsor: Aarhus University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease

Antihyperlipidemic efficiency of extracts from different parts of the Sidr plant (Ziziphus spina-christi) and compare to rosuvastatin on induced hyperlipidemic rat models. (PubMed, Pak J Pharm Sci) - "Additionally, SSF group ameliorated the hematological alterations and decreased hyperlipidemia-induced organ damage more than the other extracts. In conclusion, the seed extract was the most efficient part, as it established the most positive function biomarkers, such as ALT activity, urea and creatinine, sustaining its potential for more preclinical and clinical developments."

Clinical • Journal • Preclinical • Dyslipidemia • Hematological Disorders

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Association Between Statin Use and Glaucoma Risk: A Population-Based Study. (PubMed, Invest Ophthalmol Vis Sci) - "Statin use, particularly atorvastatin and rosuvastatin, is associated with an increased risk of ocular hypertension and POAG among patients with hyperlipidemia. The risk appears to increase with longer durations of statin use."

Journal • Cardiovascular • Dyslipidemia • Glaucoma • Ophthalmology

Formulation and evaluation of rosuvastatin calcium loaded solid nanodispersions to improve its solubility. (PubMed, Ann Pharm Fr) - "According to the study, the formulation of nanodispersions may improve the solubility and lessen the side effects associated with oral administration of BCS class II drugs that are poorly aqueously soluble."

Journal • Dyslipidemia • Metabolic Disorders

Collateral damage: rhabdomyolysis from concurrent abemaciclib and rosuvastatin use. (PubMed, Breast Cancer Res Treat) - No abstract available

Journal

ROSUBREAST: Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients (clinicaltrials.gov) - P4 | N=400 | Not yet recruiting | Sponsor: Shiraz University of Medical Sciences

New P4 trial • Breast Cancer • Cardiovascular • Congestive Heart Failure • Oncology • Solid Tumor

Efficacy, Safety, Cost, and Clinical Outcomes after the Switch to Generic Rosuvastatin Compared with Consistent Brand-Name Atorvastatin Treatment. (PubMed, Acta Cardiol Sin) - "No significant difference was noted in cumulative MACE rate (2.70% vs. 3.89%, log-rank p = 0.265) after the switch date, and each person in the generic group had a 16% average reduction in medical expenses. Switching to generic rosuvastatin led to comparable lipid-lowering efficacy, safety, and clinical outcomes and lower medical expenses compared with consistently using brand-name atorvastatin."

Clinical data • Journal • Cardiovascular • Dyslipidemia

Curcumin in the Treatment of Kidney Disease: A Systematic Review with a Focus on Drug Interactions. (PubMed, Antioxidants (Basel)) - "The curcumin-drug interactions reviewed were: -piperine, -epigallocatechin gallate, -losartan, -ginkgolide B, -rosuvastatin, -insulin, -cilostazol, and -ginger. These interactions improve curcumin bioavailability, and synergistic anti-inflammatory/antioxidant/antifibrotic and renoprotective effects. Future research should prioritize large-scale clinical trials to evaluate the efficacy and safety of curcumin in diverse KD populations."

Journal • Review • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

Liver Adiposity Effects on Pediatric Statin (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Children's Mercy Hospital Kansas City | Trial completion date: Nov 2025 ➔ Dec 2026 | Trial primary completion date: Nov 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Obesity • Pediatrics

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Gan & Lee Pharmaceuticals. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

ReMiDy: Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis (clinicaltrials.gov) - P2/3 | N=177 | Terminated | Sponsor: Universitaire Ziekenhuizen KU Leuven | Recruiting ➔ Terminated; Due to the university's termination of its contract with the online questionnaire platform, we decided to discontinue the study before reaching the anticipated sample size.

Trial termination • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (clinicaltrials.gov) - P3 | N=975 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • APOB

Earthworm fibrinolytic enzyme A and fibrin-derived peptide Bβ15-42 attenuate atherosclerosis via the VE-Cadherin signaling pathway. (PubMed, Atheroscler Plus) - "Bβ15-42, EFEa, and rosuvastatin (ROS) were administered to evaluate their effects on atherosclerotic plaque formation and inflammatory responses...EFEa and Bβ15-42 exert protective effects against atherosclerosis via the VE-cadherin pathway. Our findings lay the groundwork for further research into the anti-atherosclerotic mechanisms of EFEa, as well as its potential for future development and application."

Journal • Atherosclerosis • Cardiovascular • Inflammation • CDH5

BASIS: Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability (clinicaltrials.gov) - P3 | N=690 | Not yet recruiting | Sponsor: Sohaib Ashraf

New P3 trial • Cardiovascular

Dicloxacillin and flucloxacillin inhibit hepatic uptake transporters - in vitro investigations and physiologically based pharmacokinetic modelling. (PubMed, bioRxiv) - "PBPK model simulations predicted no major change in rosuvastatin, a substrate for OATPs and BCRP, pharmacokinetics, when co-administered with dicloxacillin or flucloxacillin. Simulations with dicloxacillin and P-gp substrates dabigatran or digoxin also predicted limited inhibition of P-gp transport."

Journal • PK/PD data • Preclinical • Breast Cancer • Oncology • Solid Tumor • SLCO2B1

Retrospective Observational Electronic Medical Records-based Real World Study to Assess the Prevalence and Treatment of Dyslipidemia in Indian Patients. (PubMed, J Assoc Physicians India) - "Statins significantly reduced LDL, TC, and TG in patients with CAD and LDL in patients with CKD. Despite being on lipid-lowering drugs, probably due to low doses, a significant proportion of patients did not achieve the recommended LDL levels."

Journal • Observational data • Real-world evidence • Retrospective data • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Nephrology • Renal Disease

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

New P1 trial • Breast Cancer • Oncology • Solid Tumor